Overview
The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.
Description
Researchers will compare liposomal bupivacaine to bupivacaine to see if liposomal bupivacaine works better to treat acute and chronic pain after video-assisted thoracoscopic lobectomy.Participants will:1.Received liposomal bupivacaine or bupivacaine paravertebral block before surgery. 2.Keep a diary of their pain scores within 30min after recovery from anesthesia and 6h, 12h, 24h, 48h, 72h and 90d after the beginning of injection of experimental drugs.
Eligibility
Inclusion Criteria:
- Participants who scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia.
- Participants were 18 years or older.
- 18 kg/m2≤BMI≤30 kg/m2
- Participants with American Society of Anesthesiology (ASA) physical status I-III.
- Understand the significance, possible benefits, potential risks of the trial in detail.Understand the procedures and methods of this study.Willing to complete the trial in strict compliance with the clinical trial protocol.Sign the informed consent form voluntarily.
Exclusion Criteria:
- with severe cardiovascular and cerebrovascular diseases such as myocardial infarction,unstable angina pectoris,severe cardiac rhythm disorders (second- and third-degree heart block,etc.), New York Heart Association (NYHA) functional class III/IV,Ischemic stroke.
- with psychiatric disorders (such as schizophrenia,depression,etc.) and cognitive impairment.
- with sensory disorders such as hyperalgesia.
- with other bodily pain.
- allergy to amide-type local anesthetics or any of the trial drugs
- taking drugs that affect liver metabolism,corticosteroids,benzodiazepines,non-steroidal anti-inflammatory drugs(NSAIDs),opioid agonist-antagonist,central-alpha 2-agonists,anticonvulsants,antidepressants within 72h.
- with a history of alcohol or opioid abuse.
- who were pregnant or lactating.
- who were currently included in another clinical study within 3 months.